Journal
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
Volume 9, Issue 5, Pages 423-440Publisher
TAYLOR & FRANCIS AS
DOI: 10.1586/ERM.09.31
Keywords
breast cancer; c-rel; cyclin D1; cyclin E; HMTV; int-1; mouse mammary tumor virus; Myc; neu/ErbB2/HER2; p53; prognosis; Ras; transgenic mouse
Categories
Funding
- NIH/NCI [5R01CA106314]
- American Cancer Sociery [RSG-07-207-01-MGO]
- Wake Forest University Golfers [P30CA12197GAC]
- Susan G Komen Foundation [KG080179]
- Ruth L Kirschstein National Research Service Award Institutional Research Training Grant [5T32CA079448]
- NIH
Ask authors/readers for more resources
Mouse mammary tumor virus (MMTV) long terminal repeat (LTR)-driven transgenic mice are excellent models for breast cancer as they allow for the targeted expression of various oncogenes and growth factors in neoplastic transformation of mammary glands. Numerous MMTV-LTR-driven transgenic mouse models of breast cancer have been created in the past three decades, including MMTV-neu/ErbB2, cyclin D1, cyclin E, Ras, Myc, int-1 and c-rel. These transgenic mice develop mammary tumors with different latency, histology and invasiveness, reflecting the oncogenic pathways activated by the transgene. Recently, homologous sequences of the env gene of MMTV have been identified in approximately 40% of human breast cancers, but not in normal breast or other types of cancers, suggesting possible involvement of mammary tumor virus in human breast carcinogenesis. Accumulating evidence demonstrates the association of MMTV provirus with progesterone receptor, p53 mutations and advanced-stage breast cancer. Thus, the detection of MMTV-like sequences may have diagnostic value to predict the clinical outcome of breast cancer patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available